HSBC signals a potential cooling period for the red-hot obesity drug trade.
Get this delivered to your inbox, and more info about our products and services.
The once-loved stock is on pace for its third worst session since 1972.
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Club holding Lilly stock slumped 1% Tuesday while Novo Nordisk shares jumped nearly 9%.
Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
